ClinicalTrials.gg
CompletedNCT05493761OsteoNAFLDUpdated Jul 23, 2026

Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease

A Phase 4 interventional study of Denosumab and Alendronate Sodium in Nonalcoholic Fatty Liver and Osteoporosis, Postmenopausal, sponsored by Aristotle University Of Thessaloniki. Completed at 3 sites in Greece. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Aristotle University Of Thessaloniki · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
40 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece — 3 open to participants now, 6 under way, 2 of them phase 3. Non-alcoholic Fatty Liver Disease · Greece.

Enrollment
12th of 20
72 · median 100
Started
2022
with 1 other
Phase 4
2 of 24
none open now
Registered
16th of 24
by date
Lead sponsor
3 of 24
Aristotle University Of Thessaloniki

Among the 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece, this one is the 12th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2022, is one of 2 in phase 4, and was the 16th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

3 of the 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 40 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece, or all of them as a file.
02

Study summary

Nonalcoholic fatty liver disease (NAFLD) is a chronic, metabolic liver disease that is closely related to obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) in a bidirectional mode. NAFLD affects approximately 25% of the worldwide population. NAFLD refers to a phenotypic spectrum, including steatosis, inflammation and fibrosis, which can lead to cirrhosis and hepatocellular carcinoma in a minority of patients. However, despite its high prevalence, morbidity and mortality, as well as the extensive research in the field, there is not to-date a licensed medication specifically for NAFLD.

Emerging evidence supports a potential association between NAFLD and osteoporosis; the prevalence of osteoporosis is probably higher in patients with NAFLD and, vise versa, the prevalence of NAFLD may be higher in patients with osteoporosis. In this context, it has been proposed that certain medications for osteoporosis may also prove to be beneficial to NAFLD.

Denosumab, a human monoclonal IgG2 antibody against the receptor activator of nuclear factor kappa-B (NF-κB) ligand (RANKL), is currently an established treatment for osteoporosis and other metabolic bone diseases. The axis RANKL-receptor activator of nuclear factor NF-κB (RANK)-osteoprotegerin (OPG) has been demonstrated as a key regulator of bone metabolism and, when dysregulated, it contributes to the pathogenesis of osteoporosis and other metabolic bone diseases. Interestingly, experimental studies have shown that circulating and hepatic RANKL may be upregulated in mice with diet-induced NAFLD, rendering RANKL a potential contributor to the pathogenesis of NAFLD, and ideally, a promising pharmacological target.

On the other hand, bisphosphonates, another established, first-line treatment for osteoporosis, are expected to have no significant effect on hepatic metabolism in patients with NAFLD due to their pharmacokinetics and mechanism of action.

This is a prospective non-randomized study which aims to investigate the comparative effect of denosumab versus bisphosphonates on hepatic steatosis and fibrosis in women with postmenopausal osteoporosis and concomitant NAFLD.

03

Conditions studied

  • Nonalcoholic Fatty Liver
  • Osteoporosis, Postmenopausal

Keywords

  • nonalcoholic fatty liver disease
  • hepatic steatosis
  • hepatic fibrosis
  • bisphosphonates
  • denosumab
  • postmenopausal osteoporosis
  • treatment
  • alendronate
  • nonalcoholic steatohepatitis
  • NAFLD
  • NASH
  • elastography
  • metabolic dysfunction-associated steatotic liver disease
  • metabolic dysfunction-associated steatohepatitis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women aged > 40 years
  • diagnosis of osteoporosis, or osteopenia and Fracture Assessment Risk (FRAX) score indicative for initiation of anti-osteoporotic treatment, or osteopenia and history of low-energy fracture. Evaluation of osteopenia and osteoporosis will be based on bone mineral density (BMD) of the lumbar spine and/or the femoral neck of the non-dominant hip measured with dual energy X-ray absorptiometry (DXA)
  • diagnosis of NAFLD based on non-invasive indices of hepatic steatosis
  • written

Exclusion criteria

Exclusion Criteria:

  • mean ethanol consumption >10 g/day
  • a history of other chronic liver disease (e.g., viral hepatitis, hepatitis, primary sclerosing cholangitis, primary biliary cholangitis and overlap syndromes, drug-induced liver injury, hemochromatosis, Wilson's disease, α1-antitrypsin deficiency)
  • liver cirrhosis
  • any
  • chronic kidney disease
  • uncontrolled hypothyroidism or hyperthyroidism
  • use of the following medications within a 12-month period before baseline associated with drug-induced fatty liver: interferon, tamoxifen, amiodarone, aloperidin, glucocorticosteroids, anabolic steroids, any medication against tuberculosis, epilepsy or viruses, methotrexate, parenteral nutrition
  • use of the following medications within a 12-month period before baseline associated probably with improvement in fatty liver: vitamin E, pioglitazone, insulin, glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium-glucose co-transporter-2 inhibitors (SGLT-2), orlistat, ursodeoxycholic acid
  • use of any anti-osteoporotic medication within a 12-month period before baseline, except for calcium and vitamin D
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    "Denosumab"

    35 postmenopausal women with low bone mineral density (BMD) and NAFLD will receive denosumab.

    Drug: Denosumab

  • Active comparator
    "Alendronate"

    35 postmenopausal women with low bone mineral density (BMD) and NAFLD will receive alendronate.

    Drug: Alendronate Sodium

Interventions

  • 60 mg (1ml) administered subcutaneously once every 6 months for 12 months (totally 2 injections). Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.

    Also known as: Prolia

  • DrugAlendronateStudies of AlendronateAlendronate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    70 mg (1 tablet) administered per os once weekly for 12 months. Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.

    Also known as: Fosamax

06

What researchers measure

Primary outcomes

  1. Hepatic steatosis: Ultrasound-Guided Attenuation Parameter (UGAP) measured on an ultrasound machine GE Logiq E10s.

    1. Between-within group interactions in UGAP (baseline to endpoint) 2. Between groups difference in change in UGAP (baseline to endpoint) UGAP is a non-invasive index based on the attenuation quantification of the ultrasound beam through the hepatic parenchyma, thus used for hepatic steatosis quantification. Cut-off values of \> 0.53 dB/cm/MHz, \>0.60 dB/cm/MHz, and \>0.65 dB/cm/MHz have been proposed for the diagnosis of steatosis grade S1, S2, and S3, respectively.

    Time frame: 12 months

Secondary outcomes

  1. Hepatic fibrosis: liver stiffness (LS) measured with 2D Shear Wave Elastography (2D SWE) on an ultrasound machine GE Logiq E10s.

    1. Between-within group interactions in LS (baseline to endpoint) 2. Between groups difference in change in LS (baseline to endpoint) 2D SWE is a non-invasive tool measuring the hepatic parenchyma stiffness, thus indirectly suggesting fibrosis stage (F). Cut-offs values of \<8.27 kPa, 8.27-9.39 kPa, 9.40-11.88 kPa and \>11.88 kPa have been proposed for F0-F1, F2, F3, and F4, respectively.

    Time frame: 12 months

  2. Hepatic steatosis non-invasive index: Fatty Liver Index (FLI).

    1. Between-within group interactions in FLI (baseline to endpoint) 2. Between groups difference in changes in FLI (baseline to endpoint) FLI is a non-invasive hepatic steatosis index, which is based on BMI, waist circumference, GGT and triglycerides. FLI ≥60 is associated with the presence of steatosis, while FLI \<30 rules out the presence of steatosis.

    Time frame: 12 months

  3. Hepatic steatosis non-invasive index: Hepatic Steatosis Index (HSI).

    1. Between-within group interactions in HSI (baseline to endpoint) 2. Between groups difference in changes and HSI (baseline to endpoint) HSI is a non-invasive hepatic steatosis index, which is based on AST, ALT, BMI, gender and the presence or not of T2DM. HSI ≥36 is associated with the presence of steatosis, while HSI \<30 rules out the presence of steatosis.

    Time frame: 12 months

  4. Hepatic fibrosis non-invasive index: NAFLD fibrosis score (NFS).

    1. Between-within group interactions in NFS (baseline to endpoint) 2. Between groups difference in changes in NFS (baseline to endpoint) NFS is a non-invasive hepatic fibrosis index, which is based on age, BMI, AST, ALT, platelets, albumin and the presence or not of T2DM. NFS \>0.675 is associated with high probability of advanced hepatic fibrosis (F3-F4), while NFS \<-1.455 is associated with low probability of advanced hepatic fibrosis (F3-F4).

    Time frame: 12 months

  5. Hepatic fibrosis non-invasive index: Fibrosis-4 index (FIB-4).

    1. Between-within group interactions in FIB-4 (baseline to endpoint) 2. Between groups difference in changes in FIB-4 (baseline to endpoint) FIB-4 is a non-invasive hepatic fibrosis index, which is based on age, AST, ALT and platelets. FIB-4 ≥2.67 is associated with high probability of advanced hepatic fibrosis (F3-F4), while FIB-4 \<1.3 (when age \<65 years) or \<2.0 (when age ≥65 years) is associated with low probability of advanced hepatic fibrosis (F3-F4).

    Time frame: 12 months

  6. Hepatic fibrosis non-invasive index: AST-to-Platelet Ratio Index (APRI).

    1. Between-within group interactions in APRI (baseline to endpoint) 2. Between groups difference in changes in APRI (baseline to endpoint) APRI is a non-invasive hepatic fibrosis index, which is based on AST, ALT and platelets. APRI ≥1 is associated with high probability of advanced hepatic fibrosis (F3-F4), while APRI \<0.5 is associated with low probability of advanced hepatic fibrosis (F3-F4).

    Time frame: 12 months

  7. Liver function tests: alanine aminotransferase (ALT).

    Between-within group interactions in ALT (baseline to endpoint) The normal range for ALT is 4-36 U/L, but it may be different in different laboratories. Higher values may indicate hepatocellular injury.

    Time frame: 12 months

  8. Liver function tests: aspartate aminotransferase (AST)

    Between-within group interactions in AST (baseline to endpoint) The normal range for AST is 8-33 U/L, but it may be different in different laboratories. Higher values may indicate hepatocellular injury.

    Time frame: 12 months

  9. Insulin resistance index: Homeostasis Model Assessment - Insulin Resistance (HOMA-IR)

    Between-within group interactions in HOMA-IR (baseline to endpoint) HOMA-IR is calculated by the formula: fasting glucose (mg/dl) × insulin (mU/L)/405, and indicates the degree of insulin resistance; higher scores indicate greater insulin resistance. A HOMA-IR value ≥2.5 is indicative of insulin resistance.

    Time frame: 12 months

  10. Lipid profile: total cholesterol

    Between-within group interactions in total cholesterol (baseline to endpoint) Total cholesterol levels \<200mg/dl are considered acceptable, 200-239 mg/dl are borderline high, and ≥240 mg/dl are considered high; however, these cut-offs differentiate according to other cardiovascular risk factors.

    Time frame: 12 months

  11. Lipid profile: triglycerides

    Between-within group interactions in triglycerides (baseline to endpoint) Triglycerides levels \<150mg/dl are considered acceptable, 150-199 mg/dl are borderline high, and ≥200 mg/dl are considered high.

    Time frame: 12 months

  12. Lipid profile: low-density lipoprotein cholesterol (LDL-C)

    Between-within group interactions in LDL-C (baseline to endpoint) LDL-C levels \<100mg/dl are considered optimal, 100-129 mg/dl are borderline high, and \>130 mg/dl are considered high; however, these cut-offs differentiate according to other cardiovascular risk factors.

    Time frame: 12 months

  13. Lipid profile: high-density lipoprotein cholesterol (HDL-C)

    Between-within group interactions in HDL-C (baseline to endpoint) For women, the normal range for HDL-C is 50-90 mg/dl. Higher HDL-C are regarded as better.

    Time frame: 12 months

  14. Serum adipokines: leptin

    Between-within group interactions in leptin (baseline to endpoint) For women, the normal range for leptin is 5-15 ng/ml, but it may be different for different ELISA kits.

    Time frame: 12 months

  15. Serum adipokines: adiponectin

    Between-within group interactions in adiponectin (baseline to endpoint) The normal range for adiponectin is 5-30 μg/ml, but it may be different for different ELISA kits.

    Time frame: 12 months

07

Study locations

3 sites
  • Department of Endocrinology, "Hippokration" General Hospital of Thessaloniki
    Thessaloniki, 54642, Greece
  • 1st Department of Obstetrics and Gynecology, School, of Medicine, Aristotle University of Thessaloniki
    Thessaloniki, 56403, Greece
  • 424 General Military Hospital
    Thessaloniki, 56429, Greece
08

References and documents

Publications

  • Makri E, Goulas A, Polyzos SA. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease. Arch Med Res. 2021 Jan;52(1):25-37. doi: 10.1016/j.arcmed.2020.11.010. Epub 2020 Dec 14. PubMed 33334622 ↗
  • Polyzos SA, Goulas A. Treatment of nonalcoholic fatty liver disease with an anti-osteoporotic medication: A hypothesis on drug repurposing. Med Hypotheses. 2021 Jan;146:110379. doi: 10.1016/j.mehy.2020.110379. Epub 2020 Nov 7. PubMed 33208241 ↗
  • Filip R, Radzki RP, Bienko M. Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis. Clin Interv Aging. 2018 Oct 4;13:1879-1891. doi: 10.2147/CIA.S170533. eCollection 2018. PubMed 30323574 ↗
  • Anastasilakis AD, Polyzos SA, Makras P. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. Eur J Endocrinol. 2018 Jul;179(1):R31-R45. doi: 10.1530/EJE-18-0056. Epub 2018 Apr 24. PubMed 29691303 ↗
  • Zhong L, Yuan J, Huang L, Li S, Deng L. RANKL Is Involved in Runx2-Triggered Hepatic Infiltration of Macrophages in Mice with NAFLD Induced by a High-Fat Diet. Biomed Res Int. 2020 May 25;2020:6953421. doi: 10.1155/2020/6953421. eCollection 2020. PubMed 32596356 ↗
  • Rinotas V, Niti A, Dacquin R, Bonnet N, Stolina M, Han CY, Kostenuik P, Jurdic P, Ferrari S, Douni E. Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice. J Bone Miner Res. 2014;29(5):1158-69. doi: 10.1002/jbmr.2112. PubMed 24127173 ↗
  • Vachliotis ID, Anastasilakis AD, Goulas A, Goulis DG, Polyzos SA. Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications. Diabetes Obes Metab. 2022 Sep;24(9):1702-1720. doi: 10.1111/dom.14774. Epub 2022 Jun 14. PubMed 35589613 ↗

Individual participant data

Plan to share: Yes — There is a plan to make IPD and related data dictionaries available

Supporting information: Study protocol, Statistical analysis plan

Time frame: 12 months after the publication of the study.

Access criteria: Yet unknown

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Jul 2026, 42 months.

Of 41 non-industry phase 4 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 46. This study's 42 months is above that.

Counting every sponsor, half of 44 studies reached it within 25 months; a quarter within 13 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2022
First posted
Aug 9, 2022
StartActual
Dec 23, 2022
Primary completionActual
Jul 16, 2026
CompletionActual
Jul 16, 2026
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05493761
Collaborators
424 General Military Hospital
Responsible party
Stergios A Polyzos (Associate Professor of Pharmacology, Aristotle University Of Thessaloniki) — Principal investigator
First posted
Aug 9, 2022
Start date
Dec 23, 2022
Primary completion
Jul 16, 2026
Completion
Jul 16, 2026
Last update
Jul 23, 2026

Study contacts

Ilias D Vachliotis, MD, PhDc
study director · School of Medicine, Aristotle University of Thessaloniki
Athanasios D Anastasilakis, MD, PhD
study director · 424 General Military Hospital, Thessaloniki, Greece
Antonis Goulas, MD, PhD
study director · School of Medicine, Aristotle University of Thessaloniki
Dimitrios G Goulis, MD, PhD
study director · School of Medicine, Aristotle University of Thessaloniki
Stergios A Polyzos, MD, PhD
principal investigator · School of Medicine, Aristotle University of Thessaloniki
Zoe A Efstathiadou, MD, PhD
study director · Department of Endocrinology, "Hippokration" General Hospital of Thessaloniki
Vasileios Rafailidis, MD, PhD
study director · School of Medicine, Aristotle University of Thessaloniki

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion